Compare Regeneron Pharmaceuticals Inc (REGN) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while ABRDN Physical Gold Shares ETF trades at $42. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while ABRDN Physical Gold Shares ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| REGN | SGOL | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $852.03 | $51.41 |
52-Week Low | $555.51 | $34.68 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
SGOL is trading at $41.48, down 1.78% with a bearish technical outlook as moving averages signal selling pressure. The stock faces resistance at $42 with support at $41, while RSI indicators show mixed signals. Recent news highlights institutional optimism for gold's medium-term prospects despite near-term volatility, with Goldman Sachs forecasting $4,900/oz gold by year-end.
The outlook remains cautiously optimistic as gold benefits from macroeconomic support including debt concerns and central bank demand. Key risks include Fed policy uncertainty and dollar strength, while technical weakness suggests potential for further consolidation before sustained upward movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
